Trivitron-Diasorin alliance will cater to the Indian InVitro Diagnostics market of around USD 500 million and Indian Immunodiagnostic market of around USD 165 million Trivitron Healthcare has announced its strategic partnership with Diasorin Group, a global leader in USD 11 billion immune segment to enter immunodiagnostic market in India. Trivitron has already made its mark as a largest player in Indian IVD division, offering products in value and premium segments. Its partnership with Diasorin will complete Trivitron's offerings in the IVD product market by entering high growth immunodiagnostics market.The DiaSorin- Trivitron partnership has formed the capital companies DiaSorin Trivitron Healthcare Private Limited, in which the parties have respectively 51% and 49% stakes. The company will directly operate in the Indian diagnostics market thus placing Trivitron as a leader in immunodiagnostic market over next 3 years.Trivitron has been a contributor in this segment wherein the company installed Immunoassay analyzersin almost 70% of labs in India. It is the first company to launch the CLIA (Chemi Luminescence Immuno Assay) platform in India.About Diasorin:With more than 40 years of international experience, the DiaSorin Group develops, produces, and distributes immunoreagent kits for clinical diagnostics. Thanks to its well established expertise, specifically in the immunodiagnostics market, DiaSorin has become 'the' in vitro diagnostics specialist. The product range mainly includes Torch, EBV, Hepatitis Virus, Tumor Markers, Thyroid, etc.